Have Cox2 inhibitors lived up to expectations?

Best Practice and Research: Clinical Gastroenterology

Volumn 18, Issue SUPPL., 2004, Pages 13-16

  Kwong, Ming Fock ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Cyclo oxygenase; Non steroidal anti inflammatory drugs; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INCIDENCE; KIDNEY DISEASE; OSTEOARTHRITIS; PEPTIC ULCER BLEEDING; PYLORUS STENOSIS; RHEUMATOID ARTHRITIS; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; PEPTIC ULCER;

EID: 10644294601     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.06.006     Document Type: Article

References (11)

1. G.A. FitzGerald C. Patrono Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433-442
2. D.Y. Graham R.H. White L.W. Moreland et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs Ann Int Med 119 1993 257-262
3. F.E. Silverstein D.Y. Graham J.R. Senior et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized doubled-blind, placebo-controlled trial Ann Int Med 123 1995 241-249
4. J.L. Goldstein F.E. Silverstein M.A. Naurang et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib. A novel COX-2 inhibitor Am J Gastroenterol 95 2000 1681-1690
5. F.E. Silverstein G. Faich J.L. Goldstein et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthriAis and rheumatoid arthritis: The class study: a randomized controlled trial JAMA 284 2000 1247-1255
6. J. Weil D. Colin-Jones et al. Langman.prophylactic aspirin and risk of peptic ulcer bleeding BMJ 310 1995 827-830
7. L.S. Simon A.L. Weaver D.Y. Graham et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomised controlled trial JAMA 282 1999 1921-1928
8. C. Hawkey L. Laine T. Simon et al. For the rofecoxib osteoarthritis endoscopy multinational study group. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized double-blind, placebo-controlled trial Arthritis Rheum 43 2000 370-377
9. C. Bombardier L. Laine A. Reicin For the VIGOR study group comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520-1528
10. L. Laine Gastrointestinal safety of coxibs and outcomes studies: What's the verdict? J Pain Symptom Manage 23 2002 S5-10
11. K.L. Chan Francis C.T. Hung Lawrence Y. Suen Bing Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis N Engl J Med 347 2002 2104-2110